AI assistant
CADOUX LIMITED Board/Management Information 2005
64620_rns_2005-07-03_0c01405d-cd68-4a81-852a-0df283fbe270.pdf
Board/Management Information
Open in viewerOpens in your device viewer
SOLBEC APPOINTS BUSINESS DEVELOPMENT MANAGER
Summary:
Solbec appoints Dr. David Sparling as Business Development Manager $\bullet$
Perth, Australia, 4th July 2005. Solbec Pharmaceuticals Limited (ASX: SBP) is pleased to announce the appointment of Dr. David Sparling to the position of Business Development Manager, Dr. Sparling joins Solbec from Agenix Ltd, where he was Commercial Counsel.
As both a lawyer and veterinary surgeon, Dr. Sparling's experience lends him considerable expertise in the scientific and commercial arenas. His unique skills will further the Company's efforts in developing Solbec's core business with the view of ultimately out-licensing Coramsine™ to the right partner.
At his previous role at Agenix. Dr. Sparling managed the company's international relationships and business development program.
This appointment reflects Solbec's commitment to creating shareholder value through the development and commercialisation of the company's product pipeline. Dr. Sparling's experience in IP management, corporate governance and business partnering will be invaluable as Solbec moves forward with its clinical program.
Dr Sparling replaces Greg Barrington who is pursuing other interests. The Company is appreciative of Mr. Barrington's efforts and wishes him well
Further information:
Tony Kiernan Chairman Solbec Pharmaceuticals Ltd. Phone +61 (08) 9446 7555 / 0418 912 843 [email protected]
Media: Rebecca Wilson Phone: +61 (02) 9237 2800 / 0417 382 391 [email protected]
Background Information
Solbec Pharmaceuticals Ltd identifies naturally-occurring compounds with potential in the development of better therapies for debilitating conditions and life-threatening diseases. The company is currently progressing its key project, Coramsine™, through Phase I/IIA clinical trials for the treatment of advanced solid tumours, and as a topical treatment for psoriasis. Solbec's two proprietary ingredients in Coramsine™ were isolated from the fruit of a weed known as the Devil's Apple (Solanum linnaeanum). They show activity against some cancers and cause potentially therapeutic changes to the immune system. In addition to human health, Coramsine™ has potential application in the areas of animal health and diagnostics. Solbec's business strategy is to partner or out-license Coramsine™ for the final stages of precommercial development and marketing.
www.solbec.com.au